Delayed-type hypersensitivity in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites

Vaccine
James G KublinR Edelman

Abstract

During the testing of the safety and immunogenicity of an adjuvanted, synthetic Plasmodium falciparum CS multiple antigen peptide (MAP) vaccine, we investigated the potential for using cutaneous delayed-type hypersensitivity (DTH) reactions as a correlate of immune response. We evaluated 27 of our volunteers for DTH reactions to intradermal inoculation (0.02 ml) of several concentrations of the MAP vaccine and adjuvant control solutions. Induration was measured 2 days after skin tests were applied. Nine of 14 vaccinees (64%) with serum, high-titered anti-MAP antibody developed positive DTH (>or=5mm induration), that first appeared by 29 days after immunization and persisted for at least 3-6 months after 1-2 more immunizations. In contrast, DTH responses were negative in eight of eight vaccinees with no or low antibody titers, and in five of five non-immunized volunteers. Biopsies of positive DTH skin test sites were histologically compatible with a DTH reaction. We conclude that the presence of T cell functional activity reflected by a positive DTH skin test response to the MAP antigen serves as another marker for vaccine immunogenicity.

References

Sep 1, 1975·Annals of Surgery·L D MacLeanJ Gordon
Jul 27, 1976·Zeitschrift Für Parasitenkunde·E J CabreraP H Silverman
Jan 22, 1972·Lancet·B M GreenwoodA Palit
Mar 28, 1995·Proceedings of the National Academy of Sciences of the United States of America·K KitamuraL J Old
Mar 1, 1993·Clinical and Experimental Dermatology·Y KuramotoH Tagami
Apr 1, 1996·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·A M LevineJ Salk
Nov 7, 1998·The Journal of Infectious Diseases·J A StouteW R Ballou
Feb 17, 1999·Proceedings of the National Academy of Sciences of the United States of America·A A Holder

❮ Previous
Next ❯

Citations

Aug 6, 2003·Current Opinion in Immunology·Alessandro Sette, John Fikes
Apr 14, 2004·Nature Reviews. Microbiology·UNKNOWN World Health Organization Special Programme for Research and Training in Tropical Diseases (WHO/TDR) 2004
May 16, 2006·Journal of Virology·Michael J McConnellMichael J Imperiale
Feb 22, 2012·International Journal of Nanomedicine·Tatiana A SlastnikovaAlexander S Sobolev
Oct 1, 2005·Journal of Peptide Science : an Official Publication of the European Peptide Society·Petr NiederhafnerJan Jezek
May 1, 2008·Expert Review of Vaccines·Rajeev K TyagiAbhinav Mehta
Oct 19, 2006·Vaccine·Marc P GirardMarie Paule Kieny
Feb 25, 2009·Expert Opinion on Biological Therapy·Chiara FalcianiLuisa Bracci

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.